International Cancer Institute

Cancer Care, Research Training & Education

Home ICI Clinical Trials

Clinical Trials at International Cancer Institute (ICI)

 

 

As part of our mission to eliminate cancer in Sub-Saharan Africa, International Cancer Institute’s clinicians and researchers conduct a number of clinical trials to effectively treat both cancer and blood diseases including sickle cell disease, haemophilia, and other bleeding disorders. 

 

Any time you or a loved one needs treatment for cancer, clinical trials are an option to think about. Learning all about them can help you talk with your doctor and decide what is right for you. We will continue to update the list of clinical trials available below for which you may be eligible.

What are clinical trials?

Clinical trials are research studies in which patients may volunteer to take part. International Cancer Institute’s Center for Data, Training, and Research uses clinical trials to find better ways to prevent, diagnose and treat cancer. Doctors and other health care professionals use treatment trials to learn more about how to fight cancer. This guide is for patients who may join a treatment trial.

 

Clinical trials are part of a long, careful process, which may take many years. First, doctors study a new treatment in the lab. Then they often study the treatment in animals. If a new treatment shows promise, doctors then test the treatment on people. Doctors do this in three to four steps or phases. Your doctor at ICI may offer you a clinical trial as a treatment option. 

Phases of Clinical Trials

 

A new treatment goes through several phases. Each phase has a different purpose. In general:

  • Phase I trials test if a new treatment is safe and look for the best way to give the treatment. Doctors also look for signs that cancer responds to the new treatment.
  • Phase II trials test if one type of cancer responds to the new treatment.
  • Phase III trials test if a new treatment is better than a standard treatment.
  • Phase IV trials find more information about long-term benefits and side effects.

 

Most of the time, when you take part in a clinical trial, you will only be in that one phase of the study. Treatments move through the phases, but patients do not.

How am I protected?

International Cancer Institute’s most important job is to protect patients. First, International Cancer Institute protects patients in clinical trials by following well-planned protocols. 

 

A protocol:

  • Explains the treatment plan.
  • Lists the medical tests that the patients will receive.
  • Gives the number of how many patients who will take part in the clinical trial.
  • Lists eligibility criteria, which are guidelines to decide who may join the clinical trial.
  • Explains safety information.

 

Second, International Cancer Institute protects patients by using a carefully structured informed consent process.

 

Third, our Institutional Review Boards (IRBs) protect patients by reviewing protocols and monitoring trials. The IRBs are committees of doctors, nurses, chaplains, social workers, lawyers, and patients. They make sure that trials follow applicable Kenyan laws and International Laws and Regulations and that those patients are protected.

 

ICI works closely with KEMRI SERU, KPPB, NACOSTI, and the sponsors of the Clinical Trials to ensure safety, compliance, and adherence to the International Conduct of Clinical Trials

Current Studies for enrolment at ICI are:

Breast Cancer

ICI has multiple clinical trials for breast cancer. Women with locally advanced or metastatic disease (Stage III or Stage IV)

  1. Hormone Receptor positive/ HER-2 positive
  2. Hormone Receptor negative/ HER-2 positive
  3. Hormone Receptor positive/ HER-2 negative

 

The following Breast Cancer Clinical Trials are Ongoing  at ICI:

  1. A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician’s Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer.
  2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Adjuvant Atezolizumab Or Placebo And Trastuzumab Emtansine For Her2-Positive Breast Cancer At High Risk Of Recurrence Following Preoperative Therapy.
  3. A Phase IIIb, Multinational, Multicenter, Randomized, Open-Label Study To Evaluate Patient Preference For Home Administration Of Fixed-Dose Combination Of Pertuzumab And Trastuzumab For Subcutaneous Administration In Participants With Early Or Locally Advanced/ Inflammatory Her2-Positive Breast Cancer.
  4. A Phase III, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of Giredestrant In Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo+Taxane In Patients With Previously Untreated Her2-Positive, Estrogen Receptor-Positive Locally-Advanced Or Metastatic Breast Cancer.

 

To check for eligibility, send your information to research@intercancer.com subject: ICI Clinical Trials or call our Clinical Trials Centre 0768 616668 and ask for the Clinical Trials Coordinator for more information.   

Esophageal Cancer

The following Esophageal Cancer Clinical Trials are available at ICI – those diagnosed with esophageal cancer with stage III or stage IV.

  1. A 3-Arm, Randomized, Blinded, Active Controlled, Phase II Study Of Ro7121661, A Pd1-Tim3 Bispecific Antibody And Ro7247669, A Pd1-Lag3 Bispecific Antibody, Compared With Nivolumab In Participants With Advanced Or Metastatic Squamous Cell Carcinoma Of The Esophagus(TaLiOs).
  2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab With Or Without Tiragolumab (Anti-TIGIT Antibody) In Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy. (SKY 07).

 

To check for eligibility, send your information to research@intercancer.com subject: ICI Clinical Trials or call our Clinical Trials Centre 0768 616668 and ask for the Clinical Trials Coordinator for more information.

Other solid tumours

At ICI, we provide Clinical Care, Treatment, and follow-ups in a multi-disciplinary team approach for all solid cancers including Prostate cancer, cervical cancer, Colon cancer, Lung Cancers, Thoracic cancers, Rectal cancers, Head and Neck cancers, Sarcomas, Liver cancers, Pancreatic cancer, Gastric cancers, Genito-urinary cancers, gynecologic cancers, and pediatric cancers.

 

Check for any care plans, book appointments, or clinical trials availability by sending your information to research@intercancer.com subject: ICI Clinical Trials or call our Clinical Trials center on 0768 616668  and ask for the Clinical Trials Coordinator for more information

Other hematologic cancers

At ICI, we provide Clinical Care, Treatments, and follow-ups in a multi-disciplinary team approach for all hematological conditions: including Multiple Myeloma, Plasmacytoma, and Myelodysplastic syndromes (MDS), Myeloproliferative disorders, Anemia, etc.

 

Check for any care plans, book appointments, or clinical trials availability by sending your information to research@intercancer.com subject: ICI Clinical Trials or call our Clinical Trials center on 0768 616668  and ask for the Clinical Trials Coordinator for more information

 

Sickle Cell Disease

ICI has multiple Sickle Cell Anemia Clinical Trials. For one to be eligible to participate, you;

 

Must have:

  1. A diagnosis-proven by hemoglobin electrophoresis
  2. Have at least 3 vaso-occlusive crisis/year that requires hospital visit/ admissions or health care professional’s intervention
  3. If using hydroxyurea, must be on a stable dose for at least 6 months.
  4. Those Not on Hydroxyurea are also welcome for assessment at ICI Clinical Care & Research Clinic if potential candidates for the studies.

 

The following Sickle Cell Disease Clinical Trials at ICI are currently recruiting:

  1. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Safety And Efficacy Of Inclacumab In Participants With Sickle Cell Disease Experiencing Vaso-Occlusive Crises(GBT 131).
  2. A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises(GBT 132).
  3. An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial(GBT 133).
  4. A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease(RBSC 2161)

 

To check for eligibility, send your information to research@intercancer.com subject: ICI Clinical Trials or call our Clinical Trials Centre 0768 616668 and ask for the Clinical Trials Coordinator for more information.               

Upcoming Research Studies at ICI

 

  1. Lung Cancer
  2. Multiple Myeloma
  3. Lymphoma
  4. Prostate Cancer
  5. Liver Cancer
  6. Cervical Cancer

 

Please Check for current studies that you may be eligible for by sending your information to info@intercancer.com subject: ICI Clinical Trials or call our center at +254 718 473 446 and ask for the Clinical Trials Coordinator for more information    

 

Patient Access Programs

 

To ensure that our cancer patients received high-quality medications that are effective and targeted to the specific cancers, International Cancer Institute has partnered with various Pharma and Foundations, to avail these novel agents to our patients, highly subsidized, since most of them cannot afford the cost of these drugs.

 

Here are some of our access programs:

 

Hodgkin Lymphoma

 

Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ACLC), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.

 

Those diagnosed with Hodgkin’s Lymphoma who have CD30+ marker on IHC/pathology and have failed their first line treatment with ABVD regimen.

 

Check for eligibility by sending your information to info@intercancer.com subject: ICI Patient Access Program or call our center on +254 718 473 446 and ask for the Oncology Pharmacist for more information

 

Breast cancer

 

Those diagnosed with HER 2-positive breast cancer and have indications for Trastuzumab.

 

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used by itself or together with other chemotherapy medication.

 

We offer a highly subsidized price for trastuzumab that is 50% or less than the market price in Kenya. This is to increase access to this life-saving targeted therapy for the majority of our patients who are poor.

 

Check for eligibility by sending your information to info@intercancer.com subject: ICI Clinical Trials or call our center on +254 718 473 446 and ask for the Oncology Pharmacist for more information

 

Non-Hodgkin’s Lymphoma (NHL) and Chronic lymphocytic leukemia (CLL)

 

Those diagnosed with Non-Hodgkin’s Lymphoma (NHL) or chronic lymphocytic leukemia and have indication for Rituximab. Those whose cancers express CD20 positivity.

 

Rituximab is a chimeric monoclonal antibody targeted against CD20 which is a surface antigen present on B cells. Therefore, it acts by depleting normal as well as pathogenic B cells while sparing plasma cells and hematopoietic stem cells as they do not express the CD20 surface antigen.

 

Rituximab may be used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and lymphocyte-predominant subtype, of Hodgkin’s Lymphoma.

 

We offer a highly subsidized price for Rituximab than the market price in Kenya. This is to increase access to this life-saving targeted therapy for the majority of our patients who are poor.

 

Check for eligibility by sending your information to info@intercancer.com subject: ICI Patient Access Program or call our center on +254 718 473 446 and ask for the Oncology Pharmacist for more information

 

Colon Cancer

 

Those diagnosed with Colon Cancer may benefit from our patient access program for Xeloda/Capecitabine.

 

Capecitabine, sold under the brand name Xeloda among others, is a chemotherapy medication used to treat breast cancer, gastric cancer, and colorectal cancer.

 

Xeloda is a prescription medicine used to treat people with:

  • cancer of the colon that has spread to lymph nodes in the area close to the colon (Dukes’ C stage), after they have surgery.
  • cancer of the colon or rectum (colorectal) that has spread to other parts of the body (metastatic).
  • breast cancer that has spread to other parts of the body (metastatic) together with another medicine called docetaxel after treatment with certain other anticancer medicines have not worked.
  • breast cancer that has spread to other parts of the body and has not improved after treatment with paclitaxel and certain other anti-cancer medicines, or who cannot receive any more treatment with certain anti-cancer medicines.

 

Check for eligibility by sending your information to info@intercancer.com subject: ICI Patient Access Program or call our center on +254 718 473 446 and ask for the Oncology Pharmacist for more information.

 

Prostate Cancer

 

Those diagnosed with metastatic Prostate cancer (Stage IV).

 

Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically, it is used together with a corticosteroid (Prednisone) for metastatic castration-resistant prostate cancer and metastatic high-risk castration sensitive prostate cancer.

 

Check for eligibility by sending your information to info@intercancer.com subject: ICI Patient Access Program or call our center on +254 718 473 446 and ask for the Oncology Pharmacist for more information.

 

We will continually update this list as more access programs become available.

Opening Hours

Monday – Friday 8.00 – 17.00
Weekends Closed
Holidays Closed

Quick Contacts

  • Address P.O. Box 8088-30100, Nandi Rd., Eldoret
  • Phone +254 718 473 446